Healthy Skepticism Library item: 673

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP.
Drug promotion.
N Engl J Med 1994; 331:(10):1350

Abstract:

Sometimes after the fact monitoring of drug promotion is not enough of a disincentive for companies to stop misleading advertising. The current Food and Drug Administration practice regarding promotion is not a complete deterent but it has some effect. Although manufacturers cannot promote drugs for unapproved indications they can respond to requests for information. There is growing support in many circles for disclosure by investigators of possible conflicts of interest. The FDA has to worry about the consequences when competition is “not always pretty.”
N Engl J Med. 1994 Nov 17;331(20):1350-3.

Keywords:
letter to the editor United States FDA Food and Drug Administration regulation of promotion REGULATION, CODES, GUIDELINES: COMPLIANCE, SANCTIONS, STANDARDS REGULATION, CODES, GUIDELINES: DIRECT GOVERNMENT REGULATION